Clinical Trials

263 enrolled 2 FDA

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05475925 2026-04-17

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

DermatologicLymphoidOther hematologic neoplasm

200 enrolled

Subcutaneous panniculitis-like T-cell lymphoma, Leukemia, Lymphoma, Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03934372 2026-04-16

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

70 enrolled

Blast Crisis, Leukemia, Lymphoma, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07504458 2026-04-16

QUATRO-APL

Phase 3 Recruiting

150 enrolled

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Promyelocytic, Acute, Hematologic Neoplasms

NCT04329728 2026-04-15

OPAL

144 enrolled

MyeloidOther hematologic neoplasmOther neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Recruiting

80 enrolled

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

171 enrolled

Phase 1 Active not recruiting

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02381886 2026-04-13

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

166 enrolled

CNSGastrointestinalMyeloidOther hematologic neoplasm

Astrocytoma, Glioblastoma, Glioma, Leukemia, Myelodysplastic Syndromes, Oligodendroglioma, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3 Recruiting

1,300 enrolled

Phase 1 Not yet recruiting

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07518329 2026-04-08

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

46 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT04256317 2026-04-03

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Phase 2/3 Recruiting

316 enrolled

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06492304 2026-04-03

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Phase 1/2 Completed

12 enrolled

Phase 3 Not yet recruiting

Leukemia, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT07509151 2026-04-03

SOUNDTRACK-C1

420 enrolled

Leukemia, Lymphoma, Leukemia, B-Cell

NCT07284433 2026-04-02

QUADvance

178 enrolled

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05886491 2026-04-01

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Terminated

16 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT06578247 2026-03-31

QuANTUM-WILD

Phase 3 Recruiting

700 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT06533579 2026-03-30

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

32 enrolled